ࡱ> q` R|bjbjqPqP::+'* 0505058h5t5ǫ66(666888$h8 uD8@8DD 662H2H2HDN .662HD2H2Hb$^66 x05\EVʨ0ǫh9nFf9^9^l8R;2H<T>888 G^888ǫDDDDd" 3$ 3   Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.q\qge兡N gPlQSShandong Xinhua Pharmaceutical Company Limited(a joint stock company established in the People s Republic of China with limited liability)(Stock Code: 0719)CONTINUING CONNECTED TRANSACTIONContinuing connected transaction between the Company and China ShandongThe Board announces that on 28 April 2011, the Company entered into an agreement with China Shandong in relation to the Company and/or its subsidiaries supplying bulk pharmaceuticals and chemical products to China Shandong from the date on which the Independent Shareholders approve the China Shandong Agreement to 31 December 2013, which is terminable upon a three months written notice in advance. As at the date of this announcement, China Shandong is a subsidiary of HHGC. HHGC is a substantial shareholder of the Company and holds 36.31% equity interest of the Company through its wholly owned subsidiary, SXPGC. Accordingly, China Shandong, being an associate of HHGC, is a connected person of the Company and the transactions contemplated under the China Shandong Agreement constitute a continuing connected transaction under Chapter 14A of the Listing Rules. The highest annual cap for 2011, 2012 and 2013 under the China Shandong Agreement is RMB180,000,000. The applicable percentage ratios (as defined in the Listing Rules) are higher than 5% on an annual basis and the annual consideration is higher than HK$10,000,000. In accordance with rule 14A.35(3) and (4) of the Listing Rules, the continuing connected transaction contemplated under the China Shandong Agreement will constitute a non-exempt continuing connected transaction and is subject to the reporting and announcement requirements under rules 14A.45 to 14A.47 of the Listing Rules, the independent shareholders approval requirements under rule 14A.48, the annual review requirements under rules 14A.37 to 14A.40 of the Listing Rules and the requirements set out in 14A.35(1) and 14A.35(2) of the Listing Rules Independent Shareholders approvalThe 2010 annual general meeting of the Company will be convened and held, among other things, to seek approval from the Independent Shareholders in relation to the China Shandong Agreement. SXPGC and its associates will be required to abstain from voting at the annual general meeting as SXPGC is an associate of HHGC.An Independent Board Committee has been established to advise the Independent Shareholders on the China Shandong Agreement and the continuing connected transaction contemplated thereunder. The Company has appointed Veda Capital Limited as its independent financial adviser to advise the Independent Board Committee and the Independent Shareholders on the terms of and the proposed annual caps for the China Shandong Agreement. A circular containing, among other things, (i) details of the China Shandong Agreement and the proposed annual caps; (ii) a letter from the Independent Board Committee to the Independent Shareholders; and (iii) recommendations of the independent financial adviser will be dispatched to the Shareholders on or before 23 May 2011. Continuing connected transaction between the Company (including its subsidiaries) and China Shandong China Shandong AgreementDate : 28 April 2011Parties : (i) the Company (ii) China ShandongPrincipal terms and conditionsOn 28 April 2011, the Company and China Shandong entered into the China Shandong Agreement in relation to the Company and/or its subsidiaries supplying bulk pharmaceuticals and chemical products to China Shandong.The term of the China Shandong Agreement runs from the date on which the Independent Shareholders approve the China Shandong Agreement to 31 December 2013 and each of the Company and China Shandong is entitled to terminate the China Shandong Agreement by a three months written notice. Payment termsThe prices of the bulk pharmaceuticals and chemical products are based on market prices and will be stated in the sales order of each transaction. Payment should be settled within the time limit based on the prices stated in the sales order of each transaction. Proposed annual capsThe proposed annual caps for the China Shandong Agreement are as follows:-2011(RMB 000)1 January, 2012 31 December, 2012(RMB 000)1 January, 2013 31 December, 2013(RMB 000)Proposed annual caps70,000140,000180,000The Company has determined the above annual caps based on the following factors:-the projected demand by China Shandong; andthe projected increase in the market prices of chemical raw materials for the production of the bulk pharmaceuticals. It is estimated that:China Shandongs demand in 2012 may double its demand in 2011 as the continuing connected transaction in 2011 will only commence after the annual general meeting to be held in June 2011; China Shandongs demand in 2013 may have approximately 15% increase compared with its demand in 2012; andthe market prices of chemical raw materials may have approximately 15% increase in 2013 compared with that in 2012. Reasons for and benefits of the continuing connected transaction between the Company and China ShandongBy virtue of the China Shandong Agreement, the Group is able to increase its revenue by selling the bulk pharmaceuticals and chemical products to China Shandong and expand the global sale of the Groups products. Accordingly, the Directors (excluding the independent non-executive Directors who will give their view upon receipt of the recommendations of the independent financial adviser) consider that:the entering into the China Shandong Agreement is in the interest of the Company and its Shareholders as a whole; the continuing connected transaction contemplated under the China Shandong Agreement are on normal commercial terms and in the ordinary and usual course of business; and the terms of the continuing connected transaction contemplated under the China Shandong Agreement are fair and reasonable.Connected RelationshipAs at the date of this announcement, China Shandong is a subsidiary of HHGC. HHGC is a substantial shareholder of the Company and holds 36.31% equity interest of the Company through its wholly owned subsidiary, SXPGC. Accordingly, China Shandong, being an associate of HHGC, is a connected person of the Company and the transactions contemplated under the China Shandong Agreement constitute a continuing connected transaction under Chapter 14A of the Listing Rules.Implications under the Listing RulesThe highest annual cap for 2011, 2012 and 2013 under the China Shandong Agreement is RMB180,000,000. The applicable percentage ratios (as defined in the Listing Rules) are higher than 5% on an annual basis and the annual consideration is higher than HK$10,000,000. In accordance with rule 14A.35(3) and (4) of the Listing Rules, the continuing connected transaction contemplated under the China Shandong Agreement will constitute a non-exempt continuing connected transaction and is subject to the reporting and announcement requirements under rules 14A.45 to 14A.47 of the Listing Rules, the independent shareholders approval requirements under rule 14A.48, the annual review requirements under rules 14A.37 to 14A.40 of the Listing Rules and the requirements set out in 14A.35(1) and 14A.35(2) of the Listing RulesInformation about the Company and China Shandong The Company is mainly engaged in the development, manufacture and sales of bulk pharmaceuticals, preparations and chemicals products.China Shandong is principally engaged in import and export trading business. Independent Shareholders approvalAn annual general meeting of the Company will be convened and held, among other things, to seek approval from the Independent Shareholders in relation to the China Shandong Agreement. SXPGC and its associates will be required to abstain from voting at the annual general meeting as SXPGC is an associate of China Shandong. An Independent Board Committee will be established to advise the Independent Shareholders on the China Shandong Agreement and the continuing connected transaction contemplated thereunder. The Company has appointed Veda Capital Limited as its independent financial adviser to advise the Independent Board Committee and the Independent Shareholders on the terms of and the proposed annual caps for the China Shandong Agreement. A circular containing, among other things, (i) details of the China Shandong Agreement; (ii) a letter from the Independent Board Committee to the Independent Shareholders; and (iii) recommendations of the independent financial adviser will be dispatched to the Shareholders on or before 23 May 2011.EFINITIONSIn this announcement, the following expressions have the meanings set out below unless the context requires otherwise:Boardmeans the board of Directors of the Company;China Shandongmeans oƖW gPlQS (China Shandong Group Ltd.), a subsidiary of HHGC; China Shandong Agreement means the written agreement entered into between the Company and China Shandong dated 28 April 2011; Company means q\qge兡N gPlQS (Shandong Xinhua Pharmaceutical Company Limited), a joint stock company incorporated in the PRC with limited liability; Directors means the directors of the Company; HHGC means ocƖW gPlQS (Hualu Holdings Group Company Limited), a wholly state-owned company, the controlling shareholder of SXPGC;Independent Board Committee means the independent board committee of the Company constituted for the purpose of the Continuing Connected Transaction, comprising three independent non-executive Directors; Independent Shareholdersmeans Shareholders other than SXPGC and its respective associates (as defined in the Listing Rules);Listing Rulesmeans the Rules Governing the Listing of Securities on the Stock Exchange;PRC means the Peoples Republic of China;RMB me7d e z { | }   x 0 2 X Z оввЪyraXyG!hh5KH\nHo(tHhCJPJo(!h2d1h6PJ]nHo(tH h6]hCJo(hnHo(tHh6]o( ho('jh6U]mHnHo(tHuhKHaJh6KH]aJo(#h 06KHPJ]aJnHo(tHh6KH]aJh6KH]aJnHo(tH(jh6KHU]aJmHnHu { } ~   x 2 X Z   $$7$8$H$Ifa$$$7$8$G$H$Ifa$ $$G$H$Ifa$$G$H$a$ $G$H$a$gd2d1G$H$$G$H$a$G$H$ $7$8$G$H$a$j|||   1 2 4 > C D E o } QTW_dlz)48NpUXýްhKHaJhKHaJo(hKHaJnHo(tH hKHhKHo(h ho(hPJnHo(tHhnHo(tHh5KH\o(h5KH\nHo(tH> $$7$8$H$Ifa$ $7$8$H$If$$7$8$H$Ifa$gd$7$7$8$H$If^7a$$$7$8$G$H$Ifa$$7$7$8$G$H$If^7a$$$7$8$G$H$Ifa$!$:ABlz +,12;CvwúÙÙÙÙ~~~q~~hKHPJnHo(tHhKHo( hKHhhCJKHaJo(hKHo(hdxhKHo(hdxhKHPJnHo(tHhdxhKH hKHhKHPJnHo(tHh5KH\aJo( h5\h5\o(h 0h 0PJnHo(tH* }#1CR_gvüױxxxxphnHtHh5KH\nHo(tHhKHnHo(tHh5KH\o(h5\o(h[o5PJ\nHo(tHhPJnHo(tHhaJo(hPJaJnHo(tHhKHo(hKHPJnHo(tHhKHaJo(hKHo( hKH ho(,}{{yjjV$77$8$G$H$^7a$$77$8$G$H$^7a$ VD^`[kd$$Ifq!!064 qa$$7$8$G$H$Ifa$$G$IfVD^ $77$8$^7 $7G$H$^7a$$77$8$G$H$^7a$$7$8$G$H$^a$$7$8$G$H$^a$$77$8$G$H$^7a$$77$8$G$H$^7a$ _bqrsw-;DEI'IXtyz~񰨖h5PJ\nHo(tH h5\h5\nHtHh5\o(h5\nHo(tHhOJQJo(hPJaJo( hKHhPJnHo(tHhKHo(hKHnHo(tH ho(hnHo(tH5'(stuz$$7$8$G$H$Ifa$$$7$8$G$H$Ifa$$87$8$G$H$^8a$$7d^7`$77$8$G$H$^7a$$77$8$G$H$^7a$$ & F nn7$8$G$H$^n`a$ e|}ƔƟƟƟwwkwkwhKHaJnHtHhKHaJo(haJo(hKHaJnHo(tHhPJnHo(tHhnHo(tHh5\mHnHo(tHuh5\mHnHo(u ho(h5PJ\nHo(tH h5\h5\o(h5\nHtHh5\nHo(tH*k\MMM$$7$8$G$H$Ifa$$$7$8$G$H$Ifa$kd$$Ifq\ ! 064qadekTNH-$ & F nn7$8$G$H$^n`a$8^87^7$\7$8$G$H$VDWDQ^`\a$kdF$$Ifq\ ! 064qa   !IJ(yj$77$8$G$H$^7a$ $7$8$G$H$a$$n7$8$G$H$a$$ & F%n7$8$G$H$a$$n7$8$G$H$^a$$n7$8$G$H$VD^a$$ & F nn7$8$G$H$^n`a$$887$8$G$H$^8`a$   !/0'()*+, ڴ||qbhKHPJaJnHo(tHhKHnHo(tHhnHo(tH ho(hKHaJhKHaJnHo(tHhKHaJo(h5KH\aJo(h5KH\aJnHo(tHhKHaJhKHPJaJnHtHhKHPJaJnHo(tHhKHaJo(hKHaJnHo(tH&() 2!3!!!Z"["r"s"F$G$l$m$''$7$8$G$H$VD^a$$77$8$G$H$^7a$$7$8$G$H$a$gd3$ & F$7$8$G$H$a$$77$8$G$H$^7a$$7$8$G$H$VD^`a$  B C j /!W!d!}!~!!!!!!!!!6"7"X"Z"["r"s""""F$G$k$m$$$$$$$$$% %$%ǿhnHo(tH ho(h5KH\aJo(hKHaJhKHaJo(hKHaJnHo(tHhnHtHh5\o(hPJnHo(tHhKHaJhKHPJaJnHo(tHhKHaJo(hKHaJnHo(tH2$%:%t%u%%%%\&&&&&&A'D'''''''''((4(5(Y(Z([(i((((((((((()ٻمم~xqxhLRKHo( hLRKH h5\hKHaJnHo(tHhCJKHOJPJaJo(hKHPJaJo(hKHPJaJnHo(tHhKHPJaJh5\o(h5KH\aJo(hKHaJo(hhPJnHo(tH ho(hnHo(tH)'''Z([(((((****++,,7G$$7$8$G$H$VD^a$$7$8$H$VD^a$$7$8$H$VD^a$gdLR$77$8$G$H$^7a$$7d^7` 7$8$H$VD^$77$8$H$^7a$))%)-).)X)i))))))))))****"*#*(*)*l*m*****++m,q,,,,,,,ֵ{nhCJOJQJaJo(hPJaJnHo(tHhaJo(hPJnHo(tHhKHaJo( ho(hKHo( hKHhLRhCJKHaJo(hLRKHPJnHo(tH hLRKHhLRKHo(hdxhLRKHo(hdxhLRKHPJnHo(tHhdxhLRKH',,,,P-Q-p-r-z-------.....@/\/j////////V0X000001 1"1*1,1.1:1R122222325262222333j3k3z3333ĺįįįĦĦˡĦĦh ho(hKHaJo(hKHnHo(tHhKHnHtHhKHo( hKHh5KH\aJo(#hLRhCJOJPJQJaJo( hLRhCJOJPJQJaJ>,,,q-r-z-{----..qLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$If7$8$G$H$$77$8$G$H$^7a$7G$WD`gd[o ...////00LLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$IfLkdn$$If0 ! 64 a800011 1.122LLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$IfLkdN$$If0 ! 64 a822526222233LLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$IfLkd.$$If0 ! 64 a83j3k3{333333LLkd~$$If0 ! 64 a8 $7$8$G$H$IfLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$333333334pp~ppppppppq&qvq~qqqqqqGrLrrrrrrrrrrsƴ󗈀uiuh5KH\aJo(h5KH\aJhKHaJhKHPJaJnHo(tHhKHaJnHo(tHh3hKHPJnHo(tH"h3B*PJaJnHo(phtHhB*aJphhB*aJo(phhKHnHo(tHhKHnHtHUhKHo( hKH'3333pppppLLkd^$$If0 ! 64 a8 $7$8$G$H$IfLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$ans Renminbi, the lawful currency of the PRC for the time being; Shareholders means the shareholders of the Company;  Stock Exchange means The Stock Exchange of Hong Kong Limited; SXPGC means q\qgeƖW gPNlQS(Shandong Xinhua Pharmaceutical Group Company Limited), a wholly-state owned company which holds and owns 36.31% of the total issued share capital of the Company and is currently the largest shareholder of the Company.By Order of the BoardShandong Xinhua Pharmaceutical Company LimitedZhang DaimingChairman28 April 2011, Zibo, PRCAs at the date of this announcement, the Board comprises: Executive Directors:Mr. Zhang Daiming (Chairman)Mr. Ren FulongMr. Du DepingMr. Zhao SongguoIndependent Non-executive Directors:Mr. Zhu pppqzq|q~qqqLLkd>$$If0 ! 64 a8 $7$8$G$H$IfLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$qrrrrrrrsswwd$< 7$8$G$H$^ a$$ 7$8$G$H$^ a$ $7$8$G$H$a$$7$8$G$H$^`a$Lkd$$If0 ! 64 a8$$7$8$G$H$Ifa$ sssss's2s3s4s5ssssssssssss|R|X|f|i|j|k|m|n|p|q|s|t|v|w|}|~||||||||}hh0JmHnHu h0Jjh0JUhYjhYUUhnHtHhnHo(tH ho(hKHaJhKHo(hKHaJo(h6KH]aJh6KH]aJo(h5KH\aJnHo(tH,sss3s4s5spsqssssssss||2|3| $$G$Ifa$$G$a$ $7$8$G$H$a$$, 7$8$G$H$^ a$BaoquanMr. Sun MinggaoMr. Kwong Chi Kit, VictorNon-executive Directors: Mr. Xu LieMr. Zhao BinPAGE 1PAGE 13|4|N|Y|f|g|h|i|j|l|m|o|fddddGkd{$$If0!64 a $$G$Ifa$Gkd$$If0!64 a o|p|r|s|u|v|||||||||||||||||||||$7$8$H$VDw^a$$4$a$&`#$|||||||||| ho(hYhhCJPJnHo(tH h0Jjh0JUhdx0JmHnHu ||||||||||||||||||||||||||||||||/0P/ =!"#$n% nu*l?xK-PNG  IHDRryJzgAMA pHYsLLXtcPLTE#$ 84*&'"51;7.*?;2-2./+40)%(#,(=9950,+'=83.627383B>B?A=C?@=QNUQNJFBJFXU\Y^[DAZWIF]ZOKHDWSQMMJKHSOD@YUVSLISPFCYV[W^ZROLHOLWTb_`\a^b^`]iftrfc}pn|ymjxupmvtywc`li~{}{wt}{rogdvsda~{xuebnkkgkholtqheqnpnspzw{x~}ƵG'IDATx}|yNg˲$Dz6d[r^ 8&!iP*`Ԙ˒lbh^ZQ@!M#'MI4mt/kvӦMO$nwvgyfgwgt7<3(Z8˱!}t%O_dKU}*meDW܇lL7{]+>IcMC|l4IzO̚*Irìi.! gKz8T*%,佫X ˏ<&K$]vUtɑ,VEzIyH.#Ϛ!tifPIѳf$]Nfx$]F䜳fX$]>.fpHl]Κatg&o#K>k.8ietgƾUFI9|֌4&(D2I$ʴ[K\Co~$]YgȎ*FC$A#eY/c#"OFj+ <#۠1kZǮWM?f5$=Y!R+K.>k*qبPެM`$oY _&I1k̊/ 6/~"G̚J]Y͠E-%B$cJME.s`SϒrĬ9ö"^}2JOfdGʶ*Fwt%YSYw-V21 1y oU2l"lJK=G5ڠ}>i&{1kF%03%)Iy?|Tjzώ|vK{Áw돳L&)sI:i<";ZKܔ{< 5$1FT=twLW|^2? 6{) _%R;I1fI~3Dv F)+I3kFf4b[jNv)I3k* 5lc557{"bcfMsWz_&[lJ@E"̚ K,iM%]r̬IUlr̙p +颐cfM ߽٨Ɇ7t1QQai˿.9fdUll)] @5mB*ëN* tQ~͗26w_pS Iw5km{ޕCL3u B]!G͚,6gt9fִ: qsѪ”%(Y(iD TW#fMA$)/pY AA8z=CfMQ`J/{]MYS:Naq&(D08J;0tCfMQ@ "4\ҝfȶsidz?t;"G͚DtGaJJrܬs"paL IE5yBRlLB ͚.BSl鱊1;K;O9kz~"bsz s[QG#gMe~6iDjcLI!GΚ~ؤS\m%]Κ~$N#)}BܬQ`]j]|sa\Q#y0Y >/ <ʔ>&FzQœt/8EXlFt<ʔ_k=+= 071ox ɕpAqQj] *>~.6Q,tzM (Q_6\#frRLQB]uIRvpzM eۣ|mwJ63;VVX RԣLQ']iѧ3O޵ˍznq(ybE>)ΉFIX88S:U ,U3sdθT`"NBBonaEBORVV+x2j ' s%NR08E=ƓGVhbf#i+zbiӪ8SR"DKnb5rSWMu;6rH[!V#3S0Ow.Bd.A#[̕`XPg #ȂE#/93fZeɌ\S{<03Ol#4 2)J{d<=`[Sԗ ˀ\S%-x,-|@u=݅}55FJ77(\dcs'`}IIFKgnFmNڳw8B?Hz,s-ډ-}ֽ-V,a \954O|\*Kѹ\nW"ZO_^6MSa&y <07t|-s<7{<2*C6m,^YZ=@9Q(iE0b+ANlzQ~O9Q_\jVv^X !*y{F0DiR#ϲӓO5||@c|ȋA^Ɍ=t*"GIgPݙ-M> 9RP86uimڰJsp>/;|(|=i :\2noi@ Wߍ}kj qg@>a19i?K]~되>>7xlgߗ@g sh.~K|~ xs>"¹7U­Ůһ4vvg^i4so8xgkSdpG+'rmS}̈́ð)wh39jkku?ʒa@VfN6:%BwSTjc9u h5#p%k _=ANWvm)eͯlW+RuKw)]zYv})K-_%)kxb[nZ TVdxN~Uwjb;? bPVWȵ!|,<}qP ~9kZgL/g}lIV6z tNyPw\ܵ!1[gtwA[h%#N0y@d z|+C ŕ5G.Yn1<'`MMM7}dy(B#,yKg\7S;w²n r<0w :ҹ0)oux9֖~e⯖gs4[_Sۿ[ rf;G^8}EO{뢂G\Y/XId(Wp=Lh+ve7(so+}Gi'Mp_kk'KD74mфG-1 >cUƱe9 +5?r/:i@~D Gu݅fIZ`UEN 'D%=u\ 3A~ YoaEٷs7Dޠ_E8@-J1|s )rOAO.мE%!185<Ӧi_r`/qc/*!wR?̱+[=aǎ0{̱~}ee];Mf-nz1_W<o5O_cc>YF3>xפ@r.GΏcM]G}EuT)My+78ϻﵱ7Wa=U=_sYjr uK7xCuQ_?Yf n% ؜G-Y`n9 R9؆۳˔F„܀?mG^ {:Fߘ2C7CTk=\@pFk}j&'jv r5qC[:+@ުv߈MarCij BNԓ~P-w9j| 4E"G9 eljUc9!~sS̊PSFF:"YeSC\yHf GL2;6h3c&TiWyf|;tk$o59Yh{w{QȉJN,tΐH#\2*ّ$ʥ ~G0M}"'߇ǽ#FCx#;]vkr"']yVjMN\wn^ZǡWZ#Oo3w,J1G%EBOM_!X#ׯͦۡ"'rLQ5r})mx }M(%r3>QH}/yfN^܌ur"ȹOf5Z.\F|ߩch !~ kn*e#7vReUS8%!G~e`[pCheeAUsn+dz.~#GF3ܟ 9fu<' tW:H<:Kg I;N]:֜op?vԼ,Bkm܍VE8'w c$a_SPTVn58pi.7Ȋ|֜N)meX>wK*)07f^xz)G4w0oVjtP\RQ^so= PկMAwoIң_:û]ul#t0tHq}g:v.;'ѻ\^Vz9WʽRm5ݪ~yv N}Y!Pr&lj&(9f4@k|9!KE\oEqo*<#Z8kcu#QMe"w,:p/ė%"'W+S3'rN"Cr{\]^-P:~pOqL /r[+:@0#ֳ!9bb0,~[;|oB-l$rS't| !G4>ޱ ANg\RSVtDåZ-rTuif=˿1ȭ$K!O8f;`ŽsݦFvzozpWލ+++^=aG>@W2۱ή^=":۷{Eeu}sǂX>h#'Jg 3'U y>K ;rMyUQ v77- ?r*3arCޛ}u7^=n^n7]Vjz~T,PT|' %zo^ IL]" *^e6rg2OCy|l oPVmR rK?1f>B7pvk^77eT$r*gFE/AFj69iF= )N75u cy~iFƧ s|n14#kꑎ,EwA"^(m<x$|Drn=2P Wʻ Sp J<񉲋Jܔ3U=F/5>JtM"@4j|:@ !,rE/*քU5lώU}Mmy=wMu%{nA܇+ߒnzkݼhMBt#`+iyWw T?%EeM}'jӖb76f5`D<$Z $}7uQdk"%Z CrŃ⏤79#㦪5ǥDxOQEWaTnePu}?L(*hc^*R^QbEP/{ |%.#;f?d ?iKz $"l+is=x(J|kc.85`(hJ(l_sY^c%NQHiЕĶXĻCY#+=raDF+CBb~X?ĉx >< ptAwEԜӇjZRI7f. qmZ8CbeA!x%%p/ =K5Q$ݴkG\#^UC6I7rfU;o6n^6 _)ꊝeml 1vi,w.x4̉J.8IoIýlw'kmb JSQ>c釐<7 HһGGZSKG{WD{s{i\^6 <$=ߍq3htcS<W} 4|lMbϛvU*=8N1g,3{6]"Iqԋ[$|V'[g 4rgrH:X^6rWoqH8*n+t0E}hW f%&PQ U籤CE<L%.Iq`JmDCB*KHPJaJnHtH$A@$ ؞k=W[SOFi@F nfh*KHOJPJQJnHtHhS@h ckee,g)ۏ 3$$7$8$G$H$^a$KHPJWDFnHtH.. yblFhe,gCJaJpOpChar Char Char Chard1$CJKHPJaJmHnHtHu\O\ Default1$7$8$H$%B*CJ_HaJmH nHphsH tH6O6 Default1 B*ph,O, cke1 B*ph  !"#$%&'()+_     !&"   "% $$% ##!&''  !"#$%&'(),     !"#$%&'+ {}~,-NOP+,5 6 7 8 [ \ Z [ J K ./IJ`aWXxy)4Xcdy]_?@>?^_ !ST)*MN P!Q!@"A"m#n#y#z#####($)$:$|$}$~$$$$% %%%%%%%%%N&O&P&o&p&!'"'#'>'?''''((( (/(0(1(8({(|(}((((((((())))))))*<*J*S*T*m*n*o******* + +1+A+Q+k+l+m+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++0000000000000000000000000000000000 04000000000000000h00y 0y0y 0y0y800000 00 00 00 0 0 0 0 0 0 00 00 00% 00% 00% 00000$ 00$ 00$ 00000000000800000H0H00000 0 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 00 00 0 00 0 0 0 00 0 0 00 0 0 00 0 00 0 0 0 00 0 00 00 0 0000000000000000000 00000 0 0000 0 0 0@0I00@0I00@0I00@0I00@0@0@0@0@0@0I0000000000000000000000000000000000000000000c 5 6 8 [ \ aW*MN +K00RK00K00&0lK00K00K00R&0l K00 'K00K00~K0 0TI0 0I0 00K00l  &&&)  $%),3s|| #%)+,./5<A (',.0233pqs3|o||||!"$&'(*-012346:;=?@BC|  ")!4!l,b$l?xK-}*1@>(  N _ 3 _N  S AB S  ?{+_|!LtxPt*#Y#L)L#v #*"#D#l~# N#'#,%#'#Y#O#<##,#P#*#LL#4"##|#(F( ))!)')**B*I*c*g*+++++++++++++++++++\d _bHP:$d$ %%%M&))+++++++++++++++++++333333Pydn#z###)$:$% %%%%%P&p&#'?'''( (1(8(}((((()* +++++++++++++++++++++++++++++++(>k/0h{c  uo+ :%M bU^X.` KP $Y[T^T3j s/?!c0 $%̛P& Q.'FFk4C41e$M8NyeW:Xi9AT~ZALldDNtT&_[Fd\I\FGKLjE|Lb7Q 'C U8CYR-J^sB`6sRdzke$M8 TiT3j Y[{c 7Q:%M E|Lmw-J^//?!ukxQ.'sRdi9A\IwoB`yeW:P& $%dDZAKP vW~GK&_[Fo+ Zs8f((%        Zn       r        Z)        f#h        ’                         x0>b*       oTԚ=      Gi                          f:Ob|       &"N                 :        g0       H{*       UPe       b        D        ,:        J         Lr        f6                          X"        tX        H        J                  Jmwld      6N        }`        *        ܞ        4         e        4[& 02d1!Q>LRYK3\Ewdx[o'`j83^jO4cdy##($)$:$}$~$$$% %%%%%%%O&P&p&"'#'?''''(( (0(1(8(|(}((((((()))*<** +l+m+++++@  p:$:%:&:(:)9++P@P P@P.P0Pd@PpP@P@Unknown gz Times New RomanTimes New Roman5Symbol3& z Arial;[SOSimSunC .PMingLiU????[TimesLTStd-RomanPMingLiU] Times-BoldTimes New Romana MSung-LightArial Unicode MS_ Times-RomanTimes New Roman 1h7ftf $[$[!?!),.:;?]}    " % & ' 2 t%00 0 000000013468:<>@BDOPQRTUVWZ\^ \]d([{  5 0 0 00000579;=?ACY[][dH+H+N 2qHX?Ew2~The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representationAChan_o(u7b(                           ! " # $ % & ' Oh+'0(4DP\l    The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representationAChanNormal ΢û21Microsoft Office Word@H'@@HQ@2tx$՜.+,0 X`t|  Charltons[H+   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXY[\]^_`acdefghijklmnopqrstuvwxyz{|}~Root Entry FxData Z1TablebWordDocumentSummaryInformation(DocumentSummaryInformation8CompObjm  FMicrosoft Office Word ĵ MSWordDocWord.Document.89q